Mabimmune AG (merged with Neurimmune)
Developing immune agonists with best-in-class therapeutic indices
Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off-tumor binding limit their efficacy. Mabimmune’s Reverse Translational Medicine (RTM) human monoclonal antibodies bind neo-epitopes unique the tumor microenvironment but not other tissues. Generated in humans and cloned directly from human genes, RTM antibodies have fully human germline sequences and thereby offer the lowest toxicity, off-tumor sinking, and immunogenicity risk of any other antibody class. Mabimmune is developing immune agonists from the RTM platform designed to offer best-in-class therapeutic indices.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
25.08.2022
"Innovation needs diversity" — Interview with Maria Olivares of the Innovation Hub at the University of Zürich (venturelab.swiss)
16.10.2017
Strategic Partnership with Genmab A/S
12.07.2016
CTI Start-up Label
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Technology
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
>>Venture>>
The venture business plan competition takes place every year and combines a competition, learning events and contact form in one. It is an initiative of the ETH Zurich, CTI and McKinsey.
IMD Startup Competition
The IMD Startup Competition provides an unique opportunity for regional technology startups to benefit from the help and insights of a team of dedicated, experienced IMD participants from the MBA and the Executive MBA programs.
Mabimmune AG (merged with Neurimmune)
Developing immune agonists with best-in-class therapeutic indices
Website:
www.mabimmune.com
Headquarter:
Schlieren
Foundation Date:
August 2010
Technology:
- Biotech
Sectors:
- Antibodies
- Biotech
- Cancer
- Drug development platforms
- Drug discovery
- Inflammation
- Protein drugs
Support received
